Positron emission tomography/computed tomography introduction in the clinical management of patients with suspected recurrence of ovarian cancer: A cost-effectiveness analysis

European Journal of Cancer Care

Volumn 18, Issue 6, 2009, Pages 612-619

  Mansueto, M ^a   Grimaldi, A ^a   Mangili, G ^b   Picchio, M ^a   Giovacchini, G ^a   ViganO R ^b   Messa, Cristina ^a,c   Fazio, F ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

Author keywords

Cost analysis; Cost effectiveness; Ovarian cancer; PET CT

Indexed keywords

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; ECONOMICS; EVALUATION; FEMALE; HUMAN; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARY TUMOR; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

ADULT; AGED; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 70350502824     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2008.00945.x     Document Type: Article

References (26)

1. Alzahouri K., Lejeune C., Woronoff-Lemsi M.C., Arveux P. Guillemin F. (2005) Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective. Clinical Radiology 60, 479 492.
2. Bristow R.E., del Carmen M.G., Pannu H.K., Cohade C., Zahurak M.L., Fishman E.K., Wahl R.L. Montz F.J. (2003) Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecologic Oncology 90, 519 528.
3. Cho S.M., Ha H.K., Byun J.Y., Lee J.M., Kim C.J. Nam-Koong S.E. (2002) Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer. American Journal of Roentgenology 179, 391 395.
4. Chung H.H., Kang W.J., Kim J.W., Park N.H., Song Y.S., Chung J.K., Kang S.B. Lee H.P. (2007) Role of [(18)F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. European Journal of Nuclear Medicine and Molecular Imaging 34, 480 486.
5. Comber L.A., Keith C.J., Griffiths M. Miles K.A. (2003) Solitary pulmonary nodules: impact of quantitative contrast-enhanced CT on the cost-effectiveness of FDG-PET. Clinical Radiology 58, 706 711.
6. Drummond M., Stoddart G. Torrace G. (2005) Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, Oxford, UK.
7. Gugiatti A., Grimaldi A., Rossetti C., Lucignani G., De Marchis D., Borgonovi E. Fazio F. (2004) Economic analyses on the use of positron emission tomography for the work-up of solitary pulmonary nodules and for staging patients with non-small-cell-lung-cancer in Italy. The Quarterly Journal of Nuclear Medicine and Molecular Imaging 48, 49 61.
8. Hany T.F., Steinert H.C., Goerres G.W., Buck A. von Schulthess G.K. (2002) PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 225, 575 581.
9. Hauth E.A., Antoch G., Stattaus J., Kuehl H., Veit P., Bockisch A., Kimmig R. Forsting M. (2005) Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. European Journal of Radiology 56, 263 268.
10. Heinrich S., Goerres G.W., Schafer M., Sagmeister M., Bauerfeind P., Pestalozzi B.C., Hany T.F., von Schulthess G.K. Clavien P.A. (2005) Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Annals of Surgery 242, 235 243.
11. Karlan B.Y., Hawkins R., Hoh C., Lee M., Tse N., Cane P. Glaspy J. (1993) Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecologic Oncology 51, 175 181.
12. Mangili G., Picchio M., Sironi S., Vigano R., Rabaiotti E., Bornaghi D., Bettinardi V., Crivellaro C., Messa C. Fazio F. (2007) Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. European Journal of Nuclear Medicine and Molecular Imaging 34, 658 666.
13. Mansueto M., Grimaldi A., Torbica A., Pepe G., Giovacchini G., Messa C. Fazio F. (2007) Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [(18F)]fluorodeoxyglucose PET and CT comparison. The Quarterly Journal of Nuclear Medicine and Molecular Imaging 51, 224 234.
14. Markman M. (2006) Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecologic Oncology 101, 550 551.
15. Nakamoto Y., Saga T., Ishimori T., Mamede M., Togashi K., Higuchi T., Mandai M., Fujii S., Sakahara H. Konishi J. (2001) Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. American Journal of Roentgenology 176, 1449 1454.
16. Petignat P., Joris F. Obrist R. (2000) How CA 125 is used in routine clinical practice. European Journal of Cancer 36, 1933 1937.
17. Picchio M., Sironi S., Messa C., Mangili G., Landoni C., Gianolli L., Zangheri B., Vigano R., Aletti Gde M., De Cobelli F., Del Maschio A., Ferrari A. Fazio F. (2003) Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment. The Quarterly Journal of Nuclear Medicine 47, 77 84.
18. Registri Tumori Generali (2006) I Tumori in Italia - Rapporto 2006. I dati di incidenza e mortalità dei Registri Tumori generali, 1998-2002. Epidemiologia e Prevenzione 30, 1 147.
19. Ries L.A.G., Miller B.A. Hankey B.F. (1997) SEER cancer statistics review 1973-1991. In : NIH Publications, pp. 2789 2795. National Cancer Institute, Bethesda, MD, USA.
20. van Roijen L., Essink-Bot M.L., Koopmanschap M.A., Bonsel G. Rutten F.F. (1996) Labor and health status in economic evaluation of health care. The health and labor questionnaire. International Journal of Technology Assessment in Health Care 12, 405 415.
21. Rustin G.J., Nelstrop A.E., Tuxen M.K. Lambert H.E. (1996) Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames ovary group study. Annals of Oncology 7, 361 364.
22. Simcock B., Neesham D., Quinn M., Drummond E., Milner A. Hicks R.J. (2006) The impact of PET/CT in the management of recurrent ovarian cancer. Gynecologic Oncology 103, 271 276.
23. Sironi S., Messa C., Mangili G., Zangheri B., Aletti G., Garavaglia E., Vigano R., Picchio M., Taccagni G., Maschio A.D. Fazio F. (2004) Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology 233, 433 440.
24. Topuz E., Aydiner A., Saip P., Eralp Y., Tas F., Salihoglu Y. Tenekeci N. (2000) Correlations of serum CA125 level and computerized tomography (CT) imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer. European Journal of Gynaecological Oncology 21, 599 602.
25. Torizuka T., Nobezawa S., Kanno T., Futatsubashi M., Yoshikawa E., Okada H., Takekuma M., Maeda M. Ouchi Y. (2002) Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose. European Journal of Nuclear Medicine and Molecular Imaging 29, 797 803.
26. Zimny M., Siggelkow W., Schroder W., Nowak B., Biemann S., Rath W. Buell U. (2001) 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecologic Oncology 83, 310 315. (Pubitemid 33033072)